The government’s reindustrialisation drive combined with requirement to relocate drug manufacturing in France have made contract pharmaceutical production a strategic activity, central to healthcare safety and sovereignty issues.
With the contract manufacturing market being highly competitive, our client’s challenge was to position itself to stand out in market segments offering high added value.
